Active Ingredient History
Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adolescent (Phase 2)
Bariatric Surgery (Phase 4)
Binge-Eating Disorder (Phase 2)
Blood Pressure (Phase 4)
Body Weight (Phase 4)
Bulimia Nervosa (Phase 1)
Cocaine-Related Disorders (Phase 1)
Colitis, Ulcerative (Phase 2)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 2 (Phase 4)
Drug Therapy (Phase 2)
Gout (Phase 3)
Healthy Lifestyle (Phase 4)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 2)
Hypertension (Early Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity ()
Obesity, Morbid (Phase 4)
Overweight (Phase 2)
Parkinson Disease (Phase 1)
Pediatric Obesity (Phase 4)
Polycystic Ovary Syndrome (Phase 3)
Prediabetic State (Phase 3)
Sleep Apnea Syndromes (Phase 1/Phase 2)
Substance-Related Disorders (Phase 1)
Torsades de Pointes (Phase 1)
Vascular Diseases (Phase 2)
Weight Loss (Phase 4)
Young Adult (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue